FDA Least Burdensome: Why Every Deficiency Now Needs a Stated Basis

"Least burdensome" sounds like a courtesy FDA extends when it feels like it. It isn't. Congress wrote it into the Federal Food, Drug, and Cosmetic Act in 1997, broadened it twice since, and in October 2022 FDA finalized a guidance that tells its own reviewers a deficiency without a stated reason for existing is not a deficiency that follows the agency's own policy. Most sponsors still treat least burdensome as background philosophy to cite in a cover letter. Read correctly, it is an operational constraint on how FDA is allowed to ask you for information — and a lever you are entitled to pull.

The statute, not the sentiment

The FDA Modernization Act of 1997 added the concept to the FD&C Act at §513(i)(1)(D): when FDA requests information to resolve differing technological characteristics in a 510(k) substantial-equivalence determination, it must request only what is necessary and must consider the least burdensome way to get it. The FDA Safety and Innovation Act (2012) and the 21st Century Cures Act (2016) broadened the instruction — extending it explicitly to PMA effectiveness determinations under §513(a)(3)(D), to De Novo classification, and clarifying that FDA should weigh postmarket information alongside premarket data when it can answer the same question. None of that expansion touched the evidentiary standard. It touched how FDA is required to get there.

What the 2022 guidance actually changed

FDA's foundational guidance, The Least Burdensome Provisions: Concept and Principles, defines the standard: the minimum amount of information necessary to adequately address a relevant regulatory question or issue, through the most efficient manner, at the right time. That guidance is durable but abstract — it tells reviewers what to value, not how to write a letter. The companion guidance, Developing and Responding to Deficiencies in Accordance with the Least Burdensome Provisions, finalized October 26, 2022 under a device user-fee commitment, is where the abstraction becomes a checkable requirement. It directs FDA staff to give each deficiency a clear statement of its basis: the specific issue or question the request is meant to resolve, and why the information asked for is necessary to resolve it.

• Interactive review first. FDA's stated preference for minor deficiencies is an informal phone or email exchange, resolved without a formal hold on the submission — faster for both sides when the question is narrow.
• The additional information letter carries the basis. Once a deficiency goes to writing, FDA's own guidance expects the letter to state what question the item answers, not just what document or data is requested.
• Prioritization is required, not optional. FDA is expected to list the most significant deficiencies first, rather than bury a review-critical gap among items that would not independently justify a hold.
• None of it changes the PMA or 510(k) standard. A request can be answered with less work and still be entirely valid — least burdensome is about the path, not the destination.

A deficiency without a stated basis is not a lighter version of a deficiency. Under FDA's own 2022 guidance, it's an incomplete one. Why the basis requirement matters operationally

Using it without burning the relationship

Sponsors who invoke least burdensome well do it narrowly and in writing, tied to the specific request rather than the whole review. If an additional information letter asks for a full clinical study to answer a question that a targeted bench test or an existing literature citation would resolve, the response is not to argue against evidence — it is to propose the most efficient valid alternative and ask the reviewer to confirm it closes the stated gap. That conversation belongs in Q-Submission interactions well before a formal filing, where the cost of resolving a disagreement is a meeting, not a 60-day submission issue request window against the clock. When a request genuinely has no stated basis, or asks for materially more than the question requires, that gap is worth raising with the reviewer directly, then the branch or division lead if it persists. FDA's own Center for Devices and Radiological Health has tracked "data and testing requirements; least burdensome" as a recurring category in its Ombudsman's complaint history for two decades — sponsors are not the first to have this argument, and there is an established channel for having it.

None of this substitutes for a submission built to answer FDA's likely questions the first time. Least burdensome rewards sponsors who can show their evidence maps cleanly to the regulatory question at hand — it does not rescue a package that never addressed the question. Treat the provisions as a design constraint on the submission, not a rebuttal you reach for after the deficiency letter arrives, and the letters get shorter.